Best Rising Companies To Invest In 2015

We’ve previously expressed caution in June and August 2013 about the emerging markets. We hereby do so again.

The rising tide of emerging markets since the start of the 21st century was fueled in particular by two major trends.

First, there was the rapid economic growth of China, the world’s most populous nation. Then came the aggressively easy monetary policy of the US Federal Reserve, to support our economy, the world’s largest.

China’s blistering growth, bringing it to second place among the world’s economies, created demand for a wide range of commodities, goods and services. Other emerging markets, especially those with significant natural resources, benefited most.

Then Fed policy, which slashed savings and bond yields while creating a tidal wave of liquidity, encouraged global investors to pour large sums into the fast-growth emerging markets’ equities, high-yielding bonds and direct business investments.

Best Rising Companies To Invest In 2015: Auxilio Inc (AUXO)

Auxilio, Inc. (Auxilio), incorporated on August 29, 1995, is engaged in the business of providing fully outsourced print management services to the healthcare industry. The Company is engaged in the business of providing fully-outsourced managed print services to the healthcare industry, working exclusively with hospitals throughout the United States. It provides solutions, a program and savings. It helps hospitals and health systems reduce expenses and create manageable, dependable document image management programs by managing their back-office processes. The process is initiated through a detailed assessment. The assessment is a strategic, operational and financial analysis that is performed at the customer�� premises using a combination of processes and technology for data collection and report generation. The Company�� customers include hospitals and integrated health delivery networks (IDN). Its subsidiaries include Auxilio Solutions, Inc. and e-Perception Technologies, Inc.

The Company helps hospitals and health systems to create image management programs by managing their back-office processes. The process is initiated through a detailed Image Management Assessment (IMA). The IMA is a strategic, operational and financial analysis that is performed at the customer�� premises using a combination of processes and Web-based technology for data collection and report generation. After the assessment and upon engagement, it charged the customer on a per print basis.

The Company competes with Xerox, Canon, Konica Minolta, Ricoh and Sharp.

Advisors' Opinion:

• [By CRWE]

  Today, AUXO surged (+3.26%) up +0.030 at $.950 with�200 shares in play thus far (ref. google finance Delayed: 9:30AM EDT August 23, 2013).

  AUXILIO, Inc. previously reported financial results for its quarter ended June 30, 2013.

  For the three months ended June 30, 2013, AUXILIO reported that recurring service revenues increased by $1.4 million from new contracts closed between May 2012 and April 2013; however revenues were $9.8 million, a decrease of 8% when compared to revenues of $10.7 million in the same period of 2012, due to a drop in equipment revenue. Equipment sales were $800,000 as compared to $3.1 million for the same period in 2012. Cost of revenues were $8.2 million for the three months ended June 30, 2013, as compared to $9.3 million for the same period in 2012. This drop was due to the drop in equipment sales offset by additional staffing and service costs from the higher recurring service revenue. Gross profit for the second quarter of 2013 was $1.6 million, or 17% of sales, compared to $1.4 million, or 13% of sales, for the same period of 2012. This improvement is a direct result of the large growth in new facilities that we added in 2012 coupled with the reduction in costs as AUXILIO�� program matures within these new accounts.

Best Rising Companies To Invest In 2015: Liberty Global Inc. (LBTYK)

Liberty Global, Inc. provides video, broadband Internet, and telephony services primarily in Europe and Chile. The company offers broadband services over cable distribution systems, including video, broadband Internet, and telephony; and video services through direct-to-home satellite, or through multichannel multipoint distribution systems. Its analog video services comprise basic and expanded basic programming; and digital cable services include basic and premium programming, digital video recorders, and high definition programming, as well as pay-per-view programming, such as video-on-demand and near video-on-demand. In addition, the company offers voice-over-Internet-protocol and circuit-switched telephony services, as well as mobile telephony services using third-party networks. Further, it owns programming networks that provide video programming channels to multi-channel distribution systems owned by the company and the third parties. As of December 31, 2011, the com pany owned and operated networks that passed 33,262,100 homes; and served 18,405,500 video subscribers, 8,159,300 broadband Internet subscribers, and 6,225,300 telephony subscribers. Liberty Global, Inc. was founded in 2004 and is based in Englewood, Colorado.

Advisors' Opinion:

• [By Monica Wolfe]

  Liberty Global PLC (LBTYK)

  John Burbank upped his stake by 376.63% during the second quarter. The guru purchased a total of 402,991 shares in the second quarter price range of $64.57 to $73.78, with an estimated average price of $69.23 per share. Since then the price per share has increased approximately 4.9%.

• [By GuruFocus]

  Warren Buffett (Trades, Portfolio) added to his holdings in Liberty Global PLC by 149.19%. His purchase prices were between $40.36 and $45.96, with an estimated average price of $43.34. The impact to his portfolio due to this purchase was 0.17%. His holdings were 7,346,968 shares as of 03/31/2014.

  Added: Liberty Global PLC (LBTYK)

  Warren Buffett (Trades, Portfolio) added to his holdings in Liberty Global PLC by 149.19%. His purchase prices were between $38.905 and $43.46, with an estimated average price of $41.33. The impact to his portfolio due to this purchase was 0.17%. His holdings were 7,346,968 shares as of 03/31/2014.

Top 5 Japanese Companies To Buy For 2015: Titan Pharmaceuticals Inc (TTNP)

Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.

Probuphine

Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.

Iloperidone

Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.

Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.

Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors' Opinion:

• [By CRWE]

  Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).

  Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine庐. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.

Best Rising Companies To Invest In 2015: Sensio Technologies Inc (PSN)

SENSIO Technologies Inc. (SENSIO) develops and markets stereoscopic technologies for the electronic consumer, digital broadcasting and digital cinema markets. The Company focuses on three dimensional (3D) video, develops and markets stereoscopic (3D) digital compression, decompression, and display-formatting technologies. Its solutions include content creators, games developers, broadcasters, specialty channels and digital cinemas. Its flagship technology, SENSIO 3D, allows distribution of 3D content through conventional two dimensional (2D) broadcast networks (cable, satellite, Internet Protocol) and playback on any 3D display device, as well as home theatre and digital cinema projectors. The Company operates in North America, Europe, Middle East and Oceania. Advisors' Opinion:

• [By Inyoung Hwang]

  Bovis Homes Group Plc (BVS) climbed 4 percent to 790 pence. Liberum Capital Ltd. raised its rating on the housebuilder to buy from hold. Persimmon Plc (PSN), the U.K.�� largest residential property developer, gained 2.5 percent to 1,255 pence.

Best Rising Companies To Invest In 2015: Simmons First National Corp (SFNC)

Simmons First National Corporation is a multi-bank financial holding company. As of December 31, 2011, the Company had total loans of $1.7 billion, deposits of $2.7 billion and equity capital of $408 million. As of December 31, 2011, it owned eight community banks, which are located throughout Arkansas and conduct its operations through 88 offices, of which 84 are branches, or financial centers, located in 47 communities in Arkansas, Missouri and Kansas. Its community banks are supported by its subsidiary bank, Simmons First National Bank (SFNB or lead bank), which allows its community banks to provide products and services, such as a bank-issued credit card. As of December 31, 2011, SFNB had total loans of $0.9 billion and total deposits of $1.5 billion. Simmons First Trust Company N.A., a wholly owned subsidiary of SFNB, performs the trust and fiduciary business operations for SFNB and for the Company. Simmons First Investment Group, Inc., a wholly owned subsidiary of SFNB, is a broker-dealer and performs the broker-dealer operations for SFNB. Its subsidiary banks provide complete banking services to individuals and businesses throughout the market areas they serve. These banks offer consumer (credit card and other consumer), real estate (construction, single family residential and other commercial) and commercial (commercial, agriculture and financial institutions) loans, checking, savings and time deposits, trust and investment management services and securities and investment services. In September 2012, through its wholly owned bank subsidiary, Simmons First National Bank (SFNB), it acquired assets of Truman Bank of St. Louis from the Federal Deposit Insurance Corporation (the FDIC). In October 2012, SFNB acquired Excel Bank of Sedalia from the Federal Deposit Insurance Corporation. In November 2013, the Company acquired Metropolitan National Bank. Efffective November 25, 2013, the Company acquired Rogers Bancshares Inc.

Lending Activities

During the year ended December! 31, 2011, the Company�� loan portfolio, excluding loans covered by Federal Deposit Insurance Corporation (FDIC) loss share arrangements, averaged $1.621 billion. As of December 31, 2011, total loans, excluding loans covered by FDIC loss share arrangements, were $1.580 billion. The components of the loan portfolio were loans to businesses (commercial loans, commercial real estate loans and agricultural loans) and individuals (consumer loans, credit card loans and single-family residential real estate loans).

Consumer loans consist of credit card loans, student loans and other consumer loans. As of December 31, 2011, consumer loans were $346.6 million or 21.9% of total loans. As of December 31, 2011, the student loan portfolio balance was $47.4 million. As of December 31, 2011, student loans were 3% of total loans. Real estate loans consist of construction loans, single family residential loans and commercial loans. As of December 31, 2011, real estate loans were $1.001 billion or 63.4% of total loans. As of December 31, 2011, its construction and development (C&D) loans represent 7% of its loan portfolio and commercial real estate (CRE) loans (excluding C&D) represent 34% of its loan portfolio. Commercial loans consist of commercial loans and agricultural loans. As of December 31, 2011, commercial loans were $227.2 million or 14.4% of total loans.

Investment Activities

Securities within the portfolio are classified as either held-to-maturity, available-for-sale or trading. Held-to-maturity securities include any security for which management has the positive intent and ability to hold until maturity, are carried at historical cost, adjusted for amortization of premiums and accretion of discounts. As of December 31, 2011, held-to-maturity and available-for-sale investment securities were $525.4 million and $172.2 million. As of December 31, 2011, $312.8 million, or 59.5%, of the held-to-maturity securities were invested in United States Treasury securities and o! bligation! s of the United States government agencies, 60.0% of which will mature in less than five years. In the available-for-sale securities, $153.6 million, or 89.2%, were in the United States Treasury and the United States government agency securities.

Sources of Fund

Deposits are the Company�� source of funding for earning assets and are developed through its network of 84 financial centers. It offers a range of products designed to attract and retain customers with a continuing focus on developing core deposits. Its core deposits consist of all deposits excluding time deposits of $100,000 or more and brokered deposits. As of December 31, 2011, core deposits comprised 86.5% of its total deposits. As of December 31, 2011, its total deposits were $2.65 billion. As of December 31, 2011, non-interest bearing transaction accounts were $532.3 million. As of December 31, 2011, interest bearing transaction and savings accounts were $1.240 billion. As of December 31, 2011, it had $20.6 million of brokered deposits.

As of December 31, 2011, Federal funds purchased and securities sold under agreements to repurchase were $114.8 million. As of December 31, 2011, its other short-term borrowings, consisting of the United States Treasury Tax and Loan (TT&L) Notes and short-term Federal Home Loan Bank (FHLB) borrowings were $272,000. As of December 31, 2011, its long-term debt was $120.8 million. As of December 31, 2011, the outstanding long-term debt balance includes $89.9 million in FHLB long-term advances and $30.9 million of trust preferred securities.

Advisors' Opinion:

• [By Tim Melvin]

  Finally, Simonds First National Corp. (Nasdaq: SFNC) is a Midwestern bank with 96 branches in Arkansas, Missouri, and Kansas. The stock has been strong this year, but CEO George Makris thinks there is additional upside ahead for the shares.

• [By CRWE]

  Simmons First National Corporation (Nasdaq:SFNC) reported, through its wholly-owned bank subsidiary, Simmons First National Bank (“SFNB”), that it has expanded into the St. Louis, Missouri market by acquiring approximately $282 million in assets of Truman Bank of St. Louis from the Federal Deposit Insurance Corporation (the “FDIC”).

Best Rising Companies To Invest In 2015: ServiceSource International Inc.(SREV)

ServiceSource International, Inc. manages the service contract renewals process of maintenance, support and subscription agreements for technology and technology-enabled healthcare, and life sciences companies. The company provides end-to-end management and optimization of the service contract renewals process, including data management, quoting, selling, and service revenue business intelligence. It offers an integrated solution that consists of Service Revenue Intelligence Platform, a data warehouse of transactional, analytical, and industry data that provides insight into the business; service sales teams working under its customers? brands; and Service Revenue Performance Suite, a suite of cloud applications. The company?s cloud applications include Analytics Cloud, which provides customers with dashboards to view and analyze service revenue performance; Service Sales Cloud that provides renewals analytics and pipeline management used by service sales teams; and Chan nel Sales Cloud, which offers channel partners and resellers with online access to their specific renewals opportunities and their performance. Its cloud applications also comprise eCommerce Cloud that provides self-service capabilities to end customers through a secure online portal; Installed Base Intelligence Cloud, which offers a single repository to analyze the data, to flag anomalies and missing data elements, and to identify cross-sell and up-sell opportunities; and Dynamic Quoting Cloud that provides an easy-to-use tool for sales representatives and channel partners to create and modify service renewal quotes. The company sells its solutions directly through sales representatives in North America, Latin America, Europe, the Middle East, Africa, the Asia Pacific, and Japan. ServiceSource International, Inc. was founded in 2002 and is headquartered in San Francisco, California with additional offices in Colorado, Tennessee, Ireland, the United Kingdom, Malaysia, and Si ngapore.

Advisors' Opinion:

• [By Lee Jackson]

  Service Source International Inc. (NASDAQ: SREV) is a small cap name with big possibilities. The company provides recurring revenue management contracts maintenance, support and subscription for technology and technology-enabled health care and life sciences companies. The consensus price objective for the stock is $14.

Best Rising Companies To Invest In 2015: Akamai Technologies Inc.(AKAM)

Akamai Technologies, Inc. provides content delivery and cloud infrastructure services for accelerating and improving applications over the Internet in the United States and internationally. The company offers application and cloud performance solutions to enhance the operation of the applications used by enterprises to connect with their employees, suppliers, and customers. Its solutions include Web Application Accelerator, which enables enterprises to run various applications; and IP Application Accelerator that is designed to optimize the performance, availability, and real-time sensitivity associated with IP-enabled applications delivered over Internet-related protocols. The company also provides video and software solutions that are designed to enable enterprises to execute their large file management and distribution strategies, which include media delivery solution to entertainment industry; and electronic software delivery solution that handles the distribution of s oftware for its customers. In addition, it offers Website optimization services for accelerating business-to-consumer Websites that integrate collaborative content and applications into their online architecture; security and protection solutions that address the Internet security requirements; and network operator solutions, which provide custom solutions to commercial and government customers. Further, the company provides mobile content adaptation solution; and advertising decision solutions that enable advertisers, agencies, publishers, and networks to buy and sell advertising, as well as network data feeds, Website analytics, and business performance management services. It markets and sells its services and solutions through direct sales and services organization; and through active channel partners. Akamai Technologies, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Lauren Pollock]

  Akamai Technologies Inc.(AKAM) agreed to buy Prolexic Technologies Inc. for about $370 million in cash, expanding its cybersecurity offerings. Prolexic, a provider of cloud-based security services for protecting data centers and Internet Protocol applications from distributed denial of service attacks, will be added to Akamai’s services for defending Web sites and Web applications.

Best Rising Companies To Invest In 2015: Hologic Inc.(HOLX)

Hologic Inc. develops, manufactures, and supplies diagnostic, medical imaging systems, and surgical products for the healthcare needs of women. The company operates in four segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment offers breast imaging products, such as Selenia full field digital mammography system, breast tomosynthesis, healthcome mammography products, screen-film mammography systems, SecurView workstation, CAD systems, stereotactic breast biopsy systems, breast biopsy products, breast brachytherapy products, MammoPad breast cushions, and photoconductor coatings, as well as Sentinelle medical MRI breast coils and workstations. This segment also develops a breast imaging platform, Dimensions, which utilizes a tomosynthesis technology to produce 3D images. The Diagnostics segment provides ThinPrep system, a solution for cervical cancer screening; rapid fetal fibronectin test for pre-term birth risk assessment; and hu man papillomavirus offering and InVitro diagnostics for cervical cancer tests. The GYN Surgical segment offers NovaSure system, a minimally-invasive procedure that allows physicians to treat women suffering from excessive menstrual bleeding; MyoSure system for the hysteroscopic removal of fibroids; and Adiana system, a form of permanent female contraception intended as an alternative to tubal ligation. The Skeletal Health segment provides QDR X-Ray bone densitometers that assess the bone density of fracture sites; Sahara clinical bone sonometers, which assess the bone density of heels; and Mini C-Arm imaging systems that are used to perform minimally invasive surgical procedures on a patient?s extremities. Hologic Inc. sells its products through a combination of direct sales and service forces, a network of independent distributors, and sales representatives primarily in the United States, Europe, and the Asia-Pacific. The company was founded in 1985 and is headquartered in Bedford, Massachusetts.

Advisors' Opinion:

• [By Myra Ramdenbourg]

  Hologic Inc (HOLX): Executive VP and CFO Glenn Muir sold 196,000 Shares

  On May 6, Executive VP and CFO Glenn P Muir sold 196,000 shares at an average price of $23.29. The price of the stock has increased by 4.77% since. Hologic Inc has a market cap of $6.74 billion and its shares were traded at around $24.40. The company has a P/S ratio of 2.67.

Best Rising Companies To Invest In 2015: Mylan Inc (MYL)

Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.

As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).

Generics Segment

The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.

The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.

In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.

In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.

Specialty Segment

The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.

Advisors' Opinion:

• [By Jayson Derrick]

  According to The Financial Times, Mylan (NYSE: MYL) is considering a stock offer to acquire Swedish based Meda who has a market cap of $4.5 billion. Meda's board convened and issued a statement in which it rejected Mylan's offer and that ��ll continued discussions between Meda and Mylan have been terminated without further actions.��Separately, Mylan has sued Celgene over allegations that Celgene has conducted illegal actions to keep its generic version of its Revlimid and Thalomid drugs off the market. Shares of Mylan gained 1.54 percent, closing at $50.63.

• [By Keith Speights]

  Heather Bresch
  Heather Bresch was named CEO of Mylan (NASDAQ: MYL  ) in 2012. At age 43, she is one of the youngest chief executives of a major corporation. Mylan ranks as the world's third-largest generic drugmaker and boasts a market cap of almost $12 billion with more than $7 billion in annual revenue.